表紙
市場調査レポート

NanoViricides, Inc. - 製品パイプライン分析

NanoViricides, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 203726
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
NanoViricides, Inc. - 製品パイプライン分析 NanoViricides, Inc. - Product Pipeline Review - 2016
出版日: 2016年08月24日 ページ情報: 英文 46 Pages
概要

NanoViricides, Inc.は、致死的なウイルス性感染症の治療薬を創薬・開発・商品化するバイオ製薬会社で、医学や製薬技術の他の分野においても研究を進めています。

当レポートでは、NanoViricides, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

NanoViricides, Inc.の基本情報

NanoViricides, Inc.の概要

  • 主要情報
  • 企業情報

NanoViricides, Inc.:R&Dの概要

  • 主な治療範囲

NanoViricides, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

NanoViricides, Inc.:パイプライン製品の概況

NanoViricides, Inc.

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

NanoViricides, Inc.:薬剤プロファイル

  • ADIFBase-I
  • DengueCide
  • EKCCide-I
  • HerpeCide-I
  • HIVCide-I
  • NVINF-1
  • NVINF-2
  • RabiCide-I
  • TBD
  • HIVCide-II
  • MERS-COV

NanoViricides, Inc.:パイプライン分析

NanoViricides, Inc.

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

NanoViricides, Inc.:最近のパイプライン動向

NanoViricides, Inc.:休止中のプロジェクト

NanoViricides, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • AviFluCide-I
    • FluCideHP-I

NanoViricides, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08128CDB

Summary

Global Markets Direct's, 'NanoViricides, Inc. - Product Pipeline Review - 2016', provides an overview of the NanoViricides, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NanoViricides, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of NanoViricides, Inc.
  • The report provides overview of NanoViricides, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses NanoViricides, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features NanoViricides, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate NanoViricides, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for NanoViricides, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding NanoViricides, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • NanoViricides, Inc. Snapshot
  • NanoViricides, Inc. Overview
  • Key Information
  • Key Facts
  • NanoViricides, Inc. - Research and Development Overview
  • Key Therapeutic Areas
  • NanoViricides, Inc. - Pipeline Review
  • Pipeline Products by Stage of Development
  • Pipeline Products - Monotherapy
  • NanoViricides, Inc. - Pipeline Products Glance
  • NanoViricides, Inc. - Early Stage Pipeline Products
  • Preclinical Products/Combination Treatment Modalities
  • Discovery Products/Combination Treatment Modalities
  • NanoViricides, Inc. - Drug Profiles
  • ADIFBase-I
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • DengueCide
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • EKCCide-I
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Herpecide
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • HIVCide-I
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • HIVCide-II
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • NVINF-1
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • NVINF-2
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • RabiCide-I
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecule for Cold Sores
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecule for Ebola and Marburg Infections
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecule for Genital Herpes
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecule for Shingles
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • NanoViricides, Inc. - Pipeline Analysis
  • NanoViricides, Inc. - Pipeline Products by Target
  • NanoViricides, Inc. - Pipeline Products by Route of Administration
  • NanoViricides, Inc. - Pipeline Products by Molecule Type
  • NanoViricides, Inc. - Pipeline Products by Mechanism of Action
  • NanoViricides, Inc. - Recent Pipeline Updates
  • NanoViricides, Inc. - Dormant Projects
  • NanoViricides, Inc. - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • AviFluCide-I
  • FluCideHP-I
  • NanoViricides, Inc. - Locations And Subsidiaries
  • Head Office
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • NanoViricides, Inc., Key Information
  • NanoViricides, Inc., Key Facts
  • NanoViricides, Inc. - Pipeline by Indication, 2016
  • NanoViricides, Inc. - Pipeline by Stage of Development, 2016
  • NanoViricides, Inc. - Monotherapy Products in Pipeline, 2016
  • NanoViricides, Inc. - Preclinical, 2016
  • NanoViricides, Inc. - Discovery, 2016
  • NanoViricides, Inc. - Pipeline by Target, 2016
  • NanoViricides, Inc. - Pipeline by Route of Administration, 2016
  • NanoViricides, Inc. - Pipeline by Molecule Type, 2016
  • NanoViricides, Inc. - Pipeline Products by Mechanism of Action, 2016
  • NanoViricides, Inc. - Recent Pipeline Updates, 2016
  • NanoViricides, Inc. - Dormant Developmental Projects,2016
  • NanoViricides, Inc. - Discontinued Pipeline Products, 2016

List of Figures

  • NanoViricides, Inc. - Pipeline by Top 10 Indication, 2016
  • NanoViricides, Inc. - Pipeline by Stage of Development, 2016
  • NanoViricides, Inc. - Monotherapy Products in Pipeline, 2016
  • NanoViricides, Inc. - Pipeline by Target, 2016
  • NanoViricides, Inc. - Pipeline by Route of Administration, 2016
  • NanoViricides, Inc. - Pipeline by Molecule Type, 2016
  • NanoViricides, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top